01—Abstract
Summary
Summary of the 8-K filed August 20, 2026. Cited figures are marked; the original filing is the authoritative source.
On August 20, 2026, Abbott Laboratories (ABT) disclosed agreements to resolve a portion of its litigation over its specialty preterm infant formulas.
Under the agreements, Abbott will resolve the Gill case, a July 2024 Missouri jury verdict of $495 milliona that the Missouri Court of Appeals affirmed in May 2026, along with necrotizing enterocolitis (NEC) claims on behalf of roughly 2,000 additional infants, for an aggregate of approximately $670 million. Rather than continue appealing or pay the roughly $600 million Gill judgment plus accrued interest, Abbott chose to settle. The company stresses that the agreements are a compromise of disputed claims, not an admission of liability.
The filing signals a potentially meaningful step toward containing a long-running overhang on the company's nutritionals business. Abbott cites recent favorable rulings, including a Seventh Circuit affirmance of a pretrial judgment in the first federal MDL bellwether case, a June 2026 Illinois appellate reversal of a $60 millionb verdict against Mead Johnson, and a March 2026 Florida dismissal based on the learned intermediary doctrine. Following the settlements, about 1,700 lawsuits involving roughly 12,700 infants remain pending.
Abbott says that population includes claims it considers improper, such as claims naming both Abbott and Mead Johnson without identifying the formula used, claims involving infants diagnosed with NEC before receiving any formula, claims involving infants never diagnosed with NEC, and duplicate filings across jurisdictions, and that it continues working to eliminate them. For investors, the key takeaways are the size of the cash outlay relative to the company's scale, the absence of any admission of liability, and the remaining claim count, which means the litigation is not yet resolved. The filing does not disclose the accounting impact, timing of payments, or whether the settlement amount was already reserved, so investors should look to subsequent SEC reports for those details.
02—Key points
Key Highlights
- Abbott agreed to resolve the Gill case and NEC claims for about 2,000 additional infants for an aggregate of approximately $670 million, versus roughly $600 million for the Gill judgment plus accrued interest alone.
- The settlement is explicitly a compromise of disputed claims and not an admission of liability; Abbott maintains that its preterm formulas are safe.
- The Gill verdict of $495 million (July 2024) was affirmed by the Missouri Court of Appeals in May 2026, which increased the pressure to settle rather than continue appealing.
- Recent favorable developments include a Seventh Circuit affirmance of a pretrial judgment for Abbott in the first federal MDL bellwether case (July 2026) and a Florida dismissal under the learned intermediary doctrine (March 2026).
- Approximately 1,700 lawsuits involving about 12,700 infants remain pending in federal and state courts after the agreements.
- Abbott says a portion of the remaining claims are improper, including duplicate filings, claims with no identified manufacturer, and claims involving infants never diagnosed with NEC.
- The filing does not quantify accounting impact, payment timing, or reserve treatment, so investors should await further disclosure in the next periodic report.
03—Questions
Frequently Asked Questions
How much is Abbott paying to resolve this litigation?
Abbott agreed to resolve the Gill case and NEC claims for about 2,000 additional infants for an aggregate of approximately $670 million. This compares to roughly $600 million for the Gill judgment plus accrued interest.
Does this settlement mean Abbott's formula caused NEC?
No. The agreements are described as a compromise of disputed claims and not an admission of liability. Abbott states that it remains confident in the safety of its preterm infant formulas and the science behind them.
Is the preterm formula litigation now resolved?
No. Approximately 1,700 lawsuits involving about 12,700 infants remain pending after these agreements. Abbott describes these agreements as a constructive step toward substantially resolving the overall litigation, not a complete resolution.
Why did Abbott choose to settle rather than keep appealing the Gill verdict?
According to the filing, rather than continuing to appeal or paying the judgment and accrued interest, Abbott believes the agreements are in its best long-term interest. The Missouri Court of Appeals had affirmed the Gill verdict in May 2026, which removed some of the uncertainty around the appeal.
Will this settlement affect Abbott's financial results?
The filing does not describe the accounting treatment, timing of payments, or whether the amount was previously reserved. Investors should review Abbott's upcoming quarterly and annual reports for these details.
04—Continue